R.E.C.K. Solution (QuVa Pharma) – Particulate Matter (2020)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) in Sodium Chloride solution 50 mL in 60 mL Syringe, Compounded by QuVa 519 Bloombury, NJ 08804, NDC 70092143350
Brand
QuVa Pharma, Inc.
Lot Codes / Batch Numbers
Lots: 30008721, Exp. 4/26/2020, 30008198, 30008554, Exp. 4/29/2020, 30008861, Exp. 4/30/2020, 30008859, Exp. 5/5/2020, 30008949, Exp. 5/10/2020, 30009073, Exp. 5/14/2020, 30009074, Exp. 30009138, Exp. 5/17/2020, 30009139, 30009227, Exp. 5/19/2020, 30009228, Exp. 5/20/2020, 30009387, 30009388, Exp. 5/27/2020, 30009410, 30009411, Exp. 5/28/2020, 30009413, Exp. 5/31/2020, 30009412, 30009489, Exp. 6/1/2020, 30009539, 30009563, Exp. 6/3/2020
Products Sold
Lots: 30008721, Exp. 4/26/2020; 30008198, 30008554, Exp. 4/29/2020; 30008861, Exp. 4/30/2020; 30008859, Exp. 5/5/2020; 30008949, Exp. 5/10/2020; 30009073, Exp. 5/14/2020; 30009074, Exp. 30009138, Exp. 5/17/2020; 30009139, 30009227, Exp. 5/19/2020; 30009228, Exp. 5/20/2020; 30009387, 30009388, Exp. 5/27/2020; 30009410, 30009411, Exp. 5/28/2020; 30009413, Exp. 5/31/2020; 30009412, 30009489, Exp. 6/1/2020; 30009539, 30009563, Exp. 6/3/2020
QuVa Pharma, Inc. is recalling R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) in Sodium Chloride solution 50 mL in 60 mL due to Presence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Presence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026